Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
An article from
Dive Brief
Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
Published Aug. 10, 2026
Sionna Therapeutics is developing a portfolio of cystic fibrosis drugs.
Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
Sionna's surprise cystic fibrosis trial failure sinks hopes of challenging Vertex
Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks - Sion
Sionna Therapeutics stock falls 92% after SION-719 trial failure
Vertex Pops As A Key Rival Plummets 90%
Sionna Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Sionna Therapeutics (SION)
SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics
RBC Capital Remains a Sell on Sionna Therapeutics, Inc. (SION)
